Generation of virus-like particles and use as panfilovirus vaccine
AssigneeThe United States of America as represented by the Secretary of the Army
InventorsSina Bavari, M. Javad Aman, Alan L. Schmaljohn, Kelly L. Warfield, Dana Swenson
Life of this patent
Estimating the term…
Abstract
In this application are described filovirus-like particles for both Ebola and Marburg and their use as a diagnostic and therapeutic agent as well as a filovirus vaccine. Also described is the association of Ebola and Marburg with lipid rafts during assembly and budding, and the requirement of functional rafts for entry of filoviruses into cells.
Claims58
A filovirus virus like particle (VLP) comprising filovirus envelope glycoprotein (GP) and filovirus matrix protein VP40.
A filovirus VLP, produced by expressing in a cell a polynucleotide encoding filovirus envelope glycoprotein and filovirus matrix protein VP40 such that said polynucleotide is expressed and said VLP is produced.
An Ebola VLP-producing cell comprising a mammalian cell expressing Ebola GP and VP40.
A Marburg VLP-producing cell comprising a mammalian cell expressing Marburg GP and VP40.
An Ebola VLP producing cell comprising an insect cell expressing Ebola GP and VP40.
A Marburg VLP producing cell comprising an insect cell expressing Marburg GP and VP40.
A filovirus virus like particle (VLP) comprising filovirus envelope glycoprotein (GP), filovirus matrix protein VP40, and filovirus nucleoprotein (NP).
A filovirus VLP, produced by expressing in a cell a polynucleotide encoding filovirus envelope glycoprotein, filovirus matrix protein VP40, and filovirus nucleoprotein NP, such that said polynucleotide is expressed and said VLP is produced.
An Ebola VLP-producing cell wherein said cell expresses Ebola GP, VP40, and NP.
A Marburg VLP-producing cell wherein said cell expresses Marburg GP, VP40, and NP.
Dependencies are inferred from the claim text.